US growing bumper crop for medical marijuana research
Researchers should be able to obtain material from the new crop in the fall after harvest and analyses are completed
Researchers should be able to obtain material from the new crop in the fall after harvest and analyses are completed
Marijuana is classified by the Drug Enforcement Agency (DEA) as an illegal Schedule I drug which has no accepted medical use. However, recent studies have shown that medical marijuana is effective in controlling chronic non-cancer pain, alleviating nausea and vomiting associated with chemotherapy, treating wasting syndrome associated with AIDS, and controlling muscle spasms due to multiple sclerosis.
Patients have a right to all beneficial treatments and to deny them this right violates their basic human rights.
A recent study shows that THC can prevent organ rejection in mice.
A great need exists for the development of new medications to treat pain resulting from various disease states and types of injury. Given that the endogenous cannabinoid (that is, endocannabinoid) system modulates neuronal and immune cell function, both of which play key roles in pain, therapeutics targeting this system hold promise as novel analgesics. Here we examine the preclinical and clinical evidence of various endocannabinoid system targets as potential therapeutic strategies for inflammatory and neuropathic pain conditions.
“We came up with an integrated way to smoke, so that we could get the very best flavor, and…medication.”
Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular cannabinoid-based medicines (CBM).
When you’ve got a lot on your mind a quick hit or two can make those worries disappear for a little while,
Low back pain (LBP) occurs in many patients with fibromyalgia (FM). The current study aimed to assess the possible pain and function amelioration associated with medical cannabis therapy (MCT) in this setting. This observational cross-over study demonstrates an advantage of MCT in FM patients with LBP as compared with SAT. Further randomised clinical trial studies should assess whether these results can be generalised to the FM population at large.
“Everyone is coming around to the benefits to be had from being a part of medicinal cannabis,”
Belgian hemp flower products will also need to comply with other tobacco product legislation